RT Journal Article
SR Electronic
T1 COVID-19 control measure effects suggest excess winter mortality is more sensitive to infection control than warmer temperatures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.19.20248531
DO 10.1101/2020.12.19.20248531
A1 Lucy Telfar-Barnard
A1 Michael G Baker
A1 Amanda Kvalsvig
A1 Nick Wilson
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.19.20248531.abstract
AB Background Excess winter mortality (EWM) has been attributed to both seasonal cold exposure, and to infectious disease. In 2020, New Zealand’s border management and lockdown measures successfully eliminated community transmission of SARS-CoV-2, and also largely eliminated influenza and many other respiratory viruses. This study investigates the contribution of infections and temperature to EWM and typical extended winter (May to October) deaths in this natural experiment created by New Zealand’s COVID-19 pandemic response.Methods We used age-standardised weekly deaths to measure EWM 2011 to 2019, then used historical patterns to estimate high, medium and low scenario 2020 EWMs. We then modelled typical year and 2020 heating degree day: mortality relationships to estimate relative contributions of cold temperature and infection to typical EWEDs.Results EWM 2011 to 2019 averaged 14.7% (low 11.4%, high 20.9%). In contrast, 2020 EWM was estimated at 1.6%, 2.7%, or 3.8% under high, medium, and low spring-summer mortality scenarios. Between 2011 and 2019, temperature was estimated to explain 47% of extended winter deaths, and infection 27%, with the remaining 26% attributable to the interaction between infection and temperature.Discussion The society-wide response to COVID-19 in 2020 resulted in a major reduction of winter mortality in this high-income nation with a temperate climate. In addition to influenza, other respiratory pathogens likely also make a significant contribution to EWM. Low cost protection measures such as mask wearing (eg, in residential care facilities), discouragement of sick presenteeism, and increased influenza vaccine coverage, all have potential to reduce future winter mortality.Evidence before this study Excess winter mortality (EWM) is a widely observed phenomenon, commonly attributed to physiological responses to short and long-term outdoor and indoor cold exposure (and associated increased air pollution); other seasonal physiology changes; and higher incidence of some infectious diseases. Previous estimates of EWM in New Zealand range from 10.3% to 25.6%, with influenza estimated to make up roughly a third of that excess. Internationally, deaths attributable to cold temperatures are also found outside the traditional winter period, with influenza making a large contribution to cold temperature deaths.Added value of this study This study finds that following a successful COVID-19 elimination strategy, which simultaneously prevented the annual winter influenza season, and likely other winter respiratory infections, New Zealand is likely in 2020 to experience less than a third of the usual winter mortality excess. Further, this study for the first time estimates the relative contributions of cold temperature and infection, and the interaction between the two, to New Zealand winter deaths. We estimate that of the 9.5% fewer deaths than in typical years recorded between 1 May and 31 October 2020, 92.5% were prevented by infection control measures; 1.4% by the 1.14°C warmer than average winter; and 6.1% by the interaction between infection and low temperature.Implications of all the available evidence Influenza and other infectious respiratory pathogens appear to make a much larger contribution to winter mortality than previously recognised. Low cost protection measures such as mask wearing (eg, in residential care facilities), discouragement of sick presenteeism, and increased influenza vaccine coverage, all have potential to reduce future winter deaths, and lower overall annual mortality rates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the Health Research Council of New Zealand.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Otago Human Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the study have not been shared as all data used are publicly available. Mortality data used are available from the Statistics New Zealand COVID-19 Data Portal (https://www.stats.govt.nz/experimental/covid-19-data-portal). Temperature data used are available from the New Zealand National Institute of Water and Atmospheric Research CliFlo database (https://cliflo.niwa.co.nz/). Population data used are available from Statistics New Zealand (http://nzdotstat.stats.govt.nz).